SEATTLE, July 20, 2016 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA products to correct life-threatening inherited liver diseases in children, today announced the appointment of Gordon Brandt, M.D., as chief medical officer. The addition of Dr. Brandt, a recognized industry leader in clinical development, bolsters PhaseRx's strategy of assembling a world-class executive team.
"We are very excited to welcome Dr. Brandt as our chief medical officer," said Robert W. Overell, Ph.D., president and chief executive officer. "He is an accomplished executive experienced in the development of RNA therapeutics who brings years of experience in drug development, including preclinical, clinical and regulatory affairs."
Dr. Brandt previously served as PhaseRx's chief clinical advisor, and has been working with the company for five years. Prior to this, he served as president and executive vice president of clinical research and medical affairs for Nastech Pharmaceutical Company Inc. (which became MDRNA Inc.), where he worked to develop nucleic acid therapeutics. Previously, Dr. Brandt worked at Sonus Pharmaceuticals, Inc., a developer of oncology drugs, where he held the positions of vice president, clinical and regulatory affairs, and director of medical affairs. Dr. Brandt graduated from Yale University with a B.S. degree in engineering science, received an M.D. from the University of California, San Francisco, and completed his residency training in internal medicine at Kaiser Hospital in San Francisco. He has worked in the medical device, biologic, and drug fields for more than 30 years, and has successfully led both US and EU drug approval programs.
PhaseRx is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening, inherited liver diseases in children. PhaseRx's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The company's i-ERT approach is enabled by its proprietary Hybrid mRNA TechnologyTM platform and is applicable to a significant number of inherited liver diseases. PhaseRx is headquartered in Seattle. For more information, please visit www.phaserx.com.
Head of Investor Relations
Forward Health Communications, Inc.
Robert H. Uhl
Westwicke Partners, LLC
SOURCE PhaseRx, Inc.